{"entity":{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","aka":[],"tldr":"Hematologist who chairs the Cancer Center CUN internal scientific committee and is one of the most influential clinical investigators in multiple myeloma.","summary":"Jesús San Miguel presides over the Internal Scientific Committee of the Cancer Center Clínica Universidad de Navarra and is Director of Clinical and Translational Medicine at the University of Navarra. He has led numerous pivotal trials in multiple myeloma with the Spanish Myeloma Group (GEM/PETHEMA) and pioneered flow-cytometry-based minimal residual disease assessment. He has received the Ham-Wasserman and Waldenström awards among other international recognitions.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=San-Miguel+JF%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","multiple myeloma","hematology"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cun-navarra"],"pathways":[],"terms":[],"trials":["cartitude-4"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, Internal Scientific Committee","institutionId":"cun-navarra","specialisms":["Multiple myeloma","Hematology","Minimal residual disease"],"profiles":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=San-Miguel+JF%5BAuthor%5D"}],"papers":[{"title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30124-3"},{"title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","journal":"The Lancet Oncology","year":2013,"doi":"10.1016/s1470-2045(13)70380-2"},{"title":"Defining and treating high-risk multiple myeloma","journal":"Leukemia","year":2015,"doi":"10.1038/leu.2015.209"}]},"route":"/people/jesus-san-miguel/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"institution":[{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/"}],"trial":[{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/"}]}}